FTC Grants Early Termination for Servier's Tender Offer for Day One Bio
DAWN has more than doubled off its 52-week low of $5.635.
Summary
The FTC has granted early termination of the HSR waiting period, fulfilling a major regulatory condition for Servier's acquisition of Day One Biopharmaceuticals.
Key Events · M&A and Partnerships · DAWN
-
HSR Waiting Period Terminated
The Federal Trade Commission (FTC) granted early termination of the waiting period under the HSR Act on April 7, 2026, at 1:37 p.m., Eastern Time.
-
Key Acquisition Condition Met
This action satisfies a critical regulatory condition for Servier's tender offer to acquire Day One Biopharmaceuticals, moving the acquisition closer to completion.
Analysis · DAWN · Life Sciences
This amendment confirms that the Federal Trade Commission (FTC) has granted early termination of the HSR Act waiting period, effective April 7, 2026. This satisfies a key regulatory condition for Servier's tender offer to acquire Day One Biopharmaceuticals, removing a significant hurdle for the acquisition to proceed. Investors should monitor the remaining conditions for the offer's completion.
At the time of this filing, DAWN was trading at $21.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $5.64 to $21.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.